Alnylam Pharmaceuticals shares hit fresh low as stock slides 27% this year

Alnylam Pharmaceuticals (ALNY) shares fell to a 52-week low of $282.71 in mid June, just above the yearly trough of $283.10, extending a slide that has knocked more than a quarter off the drugmaker's valuation in 2026.

The stock haf dropped 27 percent year-to-date and was down nearly 8 percent over the past 12 months, trimming Alnylam's market capitalization to $38.05 billion. The decline comes amid broader pressure on biotechnology stocks, with investors weighing regulatory hurdles and intensifying competition across the sector.

Despite the pullback, Alnylam remains profitable, posting diluted earnings per share of $3.95 over the trailing 12 months, with analysts forecasting continued profitability this year. Some valuation models suggest the shares are trading above fair value even after the recent declines.

Investors are now watching for strategic catalysts that could help stabilize the stock, as the company works to reassure markets following a difficult year.